Active ingredient: Selegiline Hydrochloride

Form/Route: Orally Disintegrating Tablet/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 1.25 mg X 2 tablets (Dose = 2.5 mg)
   Subjects: Normal healthy males and females, general population.
   Additional Comments: Females should not be pregnant, and if applicable, should practice
   abstinence or contraception during the study. The study tablets should be placed on top of the
   tongue and allowed to disintegrate. Subjects should avoid ingesting liquids for 5 minutes before,
   and 5 minutes after dosing. The tablets should not be swallowed. Water may be taken after 5
   minutes.

___________________________________________________________________________

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 1.25 mg X 2 tablets (Dose = 2.5 mg)
   Subjects: Normal healthy males and females, general population.
   Additional Comments: Please see comments above.

___________________________________________________________________________

Analytes to measure (in appropriate biological fluid): Selegiline and its active metabolites,
desmethylselegiline and methamphetamine, in plasma

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the
metabolite, the following data should be submitted: individual and mean concentrations, individual and
mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Bioequivalence based on (90% CI): Selegiline

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at
http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this
website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test
and reference products. Specifications will be determined upon review of the application.